Business Wire

Topcon Announces eyeRISE 2021 Virtual Symposia & Expo

18.1.2021 09:00:00 EET | Business Wire | Press release

Share

Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will host a two-day virtual symposia and expo entitled eyeRISE on February 9-10, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210117005025/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops. (Graphic: Business Wire)

eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops.

The two-day special event will feature more than three dozen globally-renowned speakers representing 17 countries and a range of specialties. Educational tracks are Building Clinical Confidence which includes topics focused on retina, glaucoma and imaging; Entering New Markets which addresses the barriers to entering myopia and dry eye management; and Too Many Patients, Not Enough Time highlighting topics such as ocular telehealth and remote diagnostics.

“We are very excited to announce eyeRISE, a one-of-a-kind, ground-breaking event that will bring together some of the most recognized names in the eye care industry to discuss the latest research and trends in patient care and practice management. In the absence of live meetings, eyeRISE provides an engaging, interactive virtual platform and offers education for a wide range of disciplines. It features solution-focused tracks for real world clinical and business management applications. eyeRISE is the culmination of Topcon’s unwavering commitment to support continued innovation in eye care,” stated Carolyn Evangelista, Global Director of Medical Affairs for Topcon Healthcare.

“eyeRISE will build on the success of our previous ISSOCT conferences and expand to include all facets of eye care, delivering clinical education for the retina, glaucoma and anterior segment subspecialties. The esteemed lecture panel will present their clinical findings on the latest research topics and innovation in eye care. It should prove to be a highly informative and enlightening meeting for all attendees,” stated ISSOCT Chairman Richard F. Spaide, MD, of Vitreous Retina Macula Consultants of New York, United States.

“Having the opportunity to network with colleagues and learn about the latest trends and technologies in eye care is critical for today’s practitioners, particularly in light of the global pandemic. eyeRISE provides practitioners with a unique opportunity to interact with the faculty and each other and gain practical tips and clinical insights. Given the challenges facing today’s eye care practitioners, eyeRISE represents a wonderful learning opportunity for all clinicians,” summarized faculty member Mingguang He, MD, PhD, Professor at the University of Melbourne, Australia.

For more information on eyeRISE or to register for the event, please visit Eyerise2021.com.

About Topcon Healthcare

Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multi-modal imaging, vendor-neutral data management, safe distancing and ground-breaking remote diagnostic technology.

A globally oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Christina Kirby
Director, Product Marketing Americas
Topcon Healthcare
E-mail: ckirby@topcon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Collaborates with Chainguard to Strengthen Software Supply Chain Security through BlueVerse™ RightLogic6.8.2026 14:30:00 EEST | Press release

LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic collaboration with Chainguard, the trusted source for open source, to strengthen software supply chain security through BlueVerse™ RightLogic, LTM's cybersecurity assessment and risk assurance framework. The collaboration enables organizations to strengthen security while maintaining the speed and agility required for AI-enabled software development. With BlueVerse RightLogic, LTM combines AI-powered cyber risk assessment with a growing ecosystem of technology partners to help enterprises identify, assess, and remediate cyber exposure while accelerating AI adoption. Chainguard strengthens the BlueVerse RightLogic ecosystem by helping enterprises secure open-source components from the outset, complementing LTM's cybersecurity services to close the gap between AI-speed discovery and enterprise-speed remediation. As AI adoption accelerates, complex software supply chains and growing relian

teamLab Borderless in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries6.8.2026 14:07:00 EEST | Press release

teamLab Borderless: MORI Building DIGITAL ART MUSEUM (teamLab Borderless) in Tokyo has welcomed over 4 Million visitors as of July 31, 2026, approximately 2 years and 5 months since its opening.*1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806672709/en/ teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Tokyo Welcomes Over 4 Million Visitors from more than 185 Countries These visitors arrived from more than 185 countries and regions. International visitors account for approximately 70% of the total number. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom and Germany. Among those who visited Japan between February 2024 and June 2026, approximately 1 in every 12 travelers from the United States, and 1 in every 9 travelers from Australia visited teamLab Borderless.*2 teamLab Borderless was selected by the U.S. based int

Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 20266.8.2026 14:00:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, and will participate in a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under eva

Purina Named as First Publicly Announced NIQ ConnectAI Charter Client6.8.2026 13:45:00 EEST | Press release

NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today named Purina as the first publicly announced client in its ConnectAI Charter Program. The announcement follows NIQ’s launch of the program with five global organizations across personal care, pet care, beauty and beverages, with additional client announcements and case studies expected as engagements advance. Through ConnectAI, NIQ forward-deployed engineers and data scientists are working within Purina’s technology environment to explore how NIQ consumer and market intelligence can support everyday AI-enabled workstreams and help teams access relevant insights more efficiently. "Understanding the needs of pet owners requires a clear view of how consumer behaviors, shopping habits, and category trends are evolving,” said Brian Donovan, Strategy and Insights, Purina. “Purina is working with NIQ to explore how its trusted intelligence can be incorporated into Purina’s everyday, AI-enabled workstreams, helping our team

Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin6.8.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of Verterans Affairs (VA) on a multi-site randomized controlled clinical trial. The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial, titled "Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression," or PIVOT, reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments. Compass will donate the study drug - COMP360, a synthetic, proprietary pharmaceutical-grade formulation of psilocybin optimized for stability and purity. Compass will support the education and training of the investigators and their training team through the provision of training

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye